Hudson Technologies, Inc. (HDSN)
NASDAQMaterialsSpecialty ChemicalsSnapshot 2026-07-23
Reading HDSN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →NASDAQMaterialsSpecialty ChemicalsSnapshot 2026-07-23
Reading HDSN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The current thesis state is cautious, reflecting mixed management execution and recent financial performance that lags behind peers.
The market seems to price HDSN as cheap compared to its peers, with a slight expectations gap. However, the fragility of earnings quality and management volatility suggests that the market does not fully account for potential risks.
Fundamentals may remain under pressure in the near term, given the company's history of earnings misses and a high probability of missing again. Management's focus on revenue growth and operational excellence shows potential, but the mixed results indicate uncertainty.
The thesis hinges on management's ability to improve execution and deliver on strategic growth initiatives. Additionally, external factors like inflation trends and performance of sector bellwethers will significantly influence HDSN's trajectory.
Over the next 1 to 3 years, HDSN's performance will depend on its operational improvements and market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide insights into Hudson's performance and future guidance. This can affect investor sentiment.
Confirms one read:The earnings report shows revenue growth. It also shows better profit margins than before.
Confirms the other:The earnings report shows falling revenue and profit margins. This raises worries about future results.
Why it matters: Earnings results show how well the company is doing. This is important for investors.
Confirms one read:The earnings report shows a big improvement from last quarter.
Confirms the other:The earnings report shows another miss or a bad outlook.
Why it matters: This guidance indicates how well Hudson is performing as it enters the peak selling season. It reflects management's confidence in revenue growth.
Confirms:Q2 revenue guidance confirmed within the range of $73 - 76 million.
Disproves:Q2 revenue guidance falls below $73 million.
Why it matters: M&A activity could drive growth and improve market position. It is a key focus for management.
Confirms:A new acquisition or partnership was announced. It is successful.
Disproves:No new M&A announcements or failed negotiations.
Why it matters: Positive revenue growth could mean the materials sector is recovering. This might help Hudson's outlook.
Confirms:Materials sector revenue growth turns positive after being near -1 percent.
Disproves:Materials sector revenue growth is still negative. This shows the sector is still shrinking.
Why it matters: A rise in gross margin shows better pricing power and efficiency. This is important for making more money in the long run.
Confirms:Gross margin improves to above 20% in Q2.
Disproves:Gross margin remains below 20% in Q2.
Why it matters: The contract with the Defense Logistics Agency brings steady income. Losing or renewing it will greatly impact Hudson's business.
Confirms one read:DLA confirms the contract renewal beyond November 2026.
Confirms the other:DLA does not renew the contract or issues a significant reduction in scope.